TOI — The Oncology Institute, Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Care Facilities·USA

Latest market price

5.13

+0.27+5.56%

Overview Short InterestFilings

TOIQT84The Oncology Institute, Inc.·NASDAQ

Overview Short InterestFilings

5.13+5.56%

Earnings

Up 5.6% — Earnings due 2026-08-06 — pre-report positioning.

Medium confidence

Loading chart...

Screen all →

SRTA+0.36%$5.57 GMRS-3.85%$12.50 CYH+1.37%$2.96 AUNA-2.29%$5.13 VMD-15.83%$9.84 AIRS+1.64%$4.96 SNDA-4.15%$38.55 TALK-1.15%$5.15

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.35	Insider Own	-	Shs Outstand	99.98M	Perf Week	-1.16%

Market Cap	512.91M	Forward P/E	-	EPS next Y	-0.02	Insider Trans	0.78%	Shs Float	49.40M	Perf Month	-2.84%

Enterprise Value	580.91M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	7.27%	Perf Quarter	26.67%

Income	-44.00M	P/S	0.94	EPS this Y	60.57%	Inst Trans	-	Short Ratio	3.89	Perf Half Y	89.30%

Sales	546.00M	P/B	-	EPS next Y	81.88%	ROA	-25.87%	Short Interest	7.27M	Perf YTD	44.10%

Book/sh	-0.16	P/C	17.09	EPS next 5Y	-	ROE	326.77%	52W High	6.67 -23.09%	Perf Year	39.78%

Cash/sh	0.30	P/FCF	-	EPS past 3/5Y	-	ROIC	-33.84%	52W Low	2.32 121.12%	Perf 3Y	440.00%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	25.91% 21.75%	Gross Margin	14.82%	Volatility	7.27% 7.36%	Perf 5Y	-48.60%

Dividend TTM	-	EV/Sales	1.06	EPS Y/Y TTM	50.70%	Oper. Margin	-5.99%	ATR (14)	0.38	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	1.17	Sales Y/Y TTM	38.93%	Profit Margin	-7.97%	RSI (14)	48.48	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	1.47	EPS Q/Q	88.24%	SMA20	-5.20%	Beta	0.36	Target Price	8.67

Payout	0.00%	Debt/Eq	29.00	Sales Q/Q	41.35%	SMA50	-0.62%	Rel Volume	0.64	Prev Close	4.86

Employees	641	LT Debt/Eq	-6.00	Earnings	Aug 06	SMA200	32.99%	Avg Volume	1.90M	Price	5.13

IPO Date	Jun 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	77.14% 3.76%	Net Debt/EBITDA	-2.55	Volume	1,221,151	Change	5.56%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-09-26	Reiterated	BTIG	Buy	$8.00 → $9.00
Jul-06-26	Initiated	Lake Street	Buy	$10
Jun-17-26	Reiterated	Needham	Buy	$5.00 → $7.00
Jun-08-26	Reiterated	BTIG	Buy	$8.00
Nov-25-25	Initiated	Needham	Buy	$5.00
Nov-11-22	Reiterated	Guggenheim	Buy	$6.00
Aug-15-22	Reiterated	Jefferies	Buy	$10

Latest News

Aug-03-26

Aug-03-2608:00AM

The Oncology Institute Rebrands as Starling Oncologyglobenewswire.com

Jul-27-26

Jul-27-2609:00AM

The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Callglobenewswire.com

Jul-09-26

Jul-09-2601:48PM

BTIG Maintains Buy on Oncology Institute, Raises Price Target to $9Benzinga

Jul-07-26

Jul-07-2602:21PM

Best Cheap Stocks Under $10 to Buy Now in Julyzacks.com

09:00AM

The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidityglobenewswire.com

Jul-06-26

Jul-06-2611:53AM

Lake Street Initiates Coverage On Oncology Institute with Buy Rating, Announces Price Target of $10Benzinga

Jul-05-26

Jul-05-2612:00PM

2 More Stocks to Buy for the AI Convergenceinvestorplace.com

Jun-29-26

Jun-29-2611:31AM

The Oncology Institute (TOI) Soars 5.3%: Is Further Upside Left in the Stock?zacks.com

Jun-28-26

Jun-28-2612:00PM

3 Stocks to Buy for the AI Convergenceinvestorplace.com

Jun-17-26

Jun-17-2606:17AM

Needham Maintains Buy on Oncology Institute, Raises Price Target to $7Benzinga

Company

The Oncology Institute (TOI) is a specialized healthcare provider delivering a full range of medical oncology services throughout the United States. Its comprehensive offerings include direct physician care, integrated on-site infusion and medication dispensing facilities, and advanced clinical trial management. The institute also provides radiation therapy, specialized outpatient programs for stem cell transplants and transfusions, and robust patient support services. Furthermore, TOI is actively involved in operating palliative care initiatives and overseeing clinical trials. These services are specifically designed to meet the needs of adult and senior cancer patients. The company maintains a significant operational footprint with 67 clinic locations. The Oncology Institute was established in 2007 and is headquartered in Cerritos, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	546	503	393	324	252	203	188	155	113
Cost of Goods Sold Incl. D&A	465	426	339	265	200	162	151	125	87
Gross Profit	82	76	54	60	52	41	37	30	26
Selling, General and Administrative Excl. Other	81	106	0	0	0	0	42	30	20
Research and Development	0	0	0	0	0	0	0	0	0
Other Operating Expense	33	7	114	137	134	87	3	3	1
Operating Income	-33	-36	-60	-77	-82	-46	-8	-3	5
Interest Expense	8	11	7	7	4	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-4	-13	3	1	86	35	-6	0	0
Net Income Before Taxes	-44	-61	-65	-83	0	-12	-15	-3	5
Income Taxes	0	0	0	0	0	-1	0	1	1
Consolidated Net Income	-44	-61	-65	-83	0	-11	-14	-4	4
Net Income From Continuing Operations	-44	-61	-65	-83	0	-11	-14	-4	4
Net Income	-44	-61	-65	-83	0	-11	-14	-4	4
EPS (Recurring)	-0.35	-0.54	-0.71	-0.92	0.00	-0.16	-0.24	-0.06	0.14
EPS (Basic, Before Extraordinaries)	-0.35	-0.54	-0.71	-0.92	0.00	-0.16	-0.24	-0.06	0.14
EPS (Diluted)	-0.35	-0.54	-0.71	-0.92	-0.21	-0.16	-0.24	-0.06	0.14
EBITDA	-29	-43	-51	-54	-68	-42	-11	0	9
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	9.56	6.54	0.06	0.47	0.48	3.17	3.39	—	—
Gross Margin	15.02	15.11	13.74	18.52	20.63	20.20	19.68	19.35	23.01
Operating Margin	-6.04	-7.16	-15.27	-23.77	-32.54	-22.66	-4.26	-1.94	4.42
Net Margin	-8.06	-12.13	-16.54	-25.62	0.00	-5.42	-7.45	-2.58	3.54
Shares Outstanding	1,018	924	75	74	73	66	59	64	64
Market Capitalization	5,222	3,289	23	151	120	644	637	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chernett Jorey	10% Owner	Jul 21 '26	Buy	5.27	18,000	94,860	10,648,858	Jul 22
Podnos Yale	Chief Medical Officer	Jul 14 '26	Option Exercise	1.90	46,904	89,134	277,501	Jul 16
Podnos Yale	Chief Medical Officer	Jul 14 '26	Sale	6.41	23,452	150,340	259,527	Jul 16
Chernett Jorey	10% Owner	Jul 10 '26	Buy	5.85	15,000	87,750	10,630,858	Jul 13
Chernett Jorey	10% Owner	Jun 23 '26	Buy	5.02	18,000	90,360	10,615,858	Jun 24
Podnos Yale	Chief Medical Officer	Jun 08 '26	Sale	5.38	23,451	126,094	259,527	Jun 09
Chernett Jorey	10% Owner	Jun 04 '26	Buy	4.75	12,000	57,000	10,579,858	Jun 05
Chernett Jorey	10% Owner	May 20 '26	Buy	4.07	33,500	136,345	10,567,858	May 21
Chernett Jorey	10% Owner	May 19 '26	Buy	4.08	35,000	142,950	10,534,358	May 21
Kaushal Mohit	Director	Apr 16 '26	Sale	3.50	38,433	134,535	172,583	Apr 16
Kaushal Mohit	Director	Apr 14 '26	Sale	3.50	57,286	200,598	211,016	Apr 16
Chernett Jorey	10% Owner	Apr 09 '26	Buy	3.10	20,000	62,000	10,499,358	Apr 13
Chernett Jorey	10% Owner	Mar 27 '26	Buy	2.96	27,429	81,190	10,479,358	Mar 30
Chernett Jorey	10% Owner	Mar 26 '26	Buy	3.15	50,000	157,500	10,451,929	Mar 27
Chernett Jorey	10% Owner	Mar 24 '26	Buy	3.11	125,000	388,750	10,401,929	Mar 25

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.